TULP4
gene geneOn this page
Also known as TUSPKIAA1397
Summary
TULP4 (TUB like protein 4, HGNC:15530) is a protein-coding gene on chromosome 6q25.3, encoding Tubby-related protein 4 (Q9NRJ4). May be a substrate-recognition component of a SCF-like ECS (Elongin-Cullin-SOCS-box protein) E3 ubiquitin ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins.
Predicted to be involved in protein ubiquitination. Located in cytoplasm.
Source: NCBI Gene 56995 — RefSeq curated summary.
At a glance
- GWAS associations: 10
- Clinical variants (ClinVar): 330 total
- MANE Select transcript:
NM_020245
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:15530 |
| Approved symbol | TULP4 |
| Name | TUB like protein 4 |
| Location | 6q25.3 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | TUSP, KIAA1397 |
| Ensembl gene | ENSG00000130338 |
| Ensembl biotype | protein_coding |
| OMIM | 619442 |
| Entrez | 56995 |
Gene structure
Transcript identifiers
Ensembl transcripts: 7 — 3 protein_coding_CDS_not_defined, 2 protein_coding, 1 nonsense_mediated_decay, 1 retained_intron
ENST00000367094, ENST00000367097, ENST00000432358, ENST00000613390, ENST00000613994, ENST00000616856, ENST00000620026
RefSeq mRNA: 2 — MANE Select: NM_020245
NM_001007466, NM_020245
CCDS: CCDS34561, CCDS34562
Canonical transcript exons
ENST00000367097 — 14 exons
| Exon | Start | End |
|---|---|---|
| ENSE00000765520 | 158493573 | 158493717 |
| ENSE00000765522 | 158489588 | 158489732 |
| ENSE00000765523 | 158481055 | 158481289 |
| ENSE00000894205 | 158498669 | 158498812 |
| ENSE00000894207 | 158494753 | 158494846 |
| ENSE00000894209 | 158479751 | 158479975 |
| ENSE00000894211 | 158461563 | 158461729 |
| ENSE00000894213 | 158452134 | 158452268 |
| ENSE00000894215 | 158448996 | 158449176 |
| ENSE00000894217 | 158429736 | 158429897 |
| ENSE00000894219 | 158413065 | 158413193 |
| ENSE00001411602 | 158501678 | 158504178 |
| ENSE00001865172 | 158506578 | 158511828 |
| ENSE00003714570 | 158312465 | 158314268 |
Expression profiles
Bgee: expression breadth ubiquitous, 274 present calls, max score 98.02.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 12.2730 / max 181.6420, expressed in 1739 samples.
FANTOM5 promoters (5 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 70831 | 5.5877 | 1520 |
| 70830 | 5.2752 | 1599 |
| 70829 | 1.1719 | 693 |
| 70832 | 0.1550 | 60 |
| 70833 | 0.0832 | 7 |
Top tissues by expression
283 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| medial globus pallidus | UBERON:0002477 | 98.02 | gold quality |
| globus pallidus | UBERON:0001875 | 97.79 | gold quality |
| corpus callosum | UBERON:0002336 | 97.50 | gold quality |
| cerebellar vermis | UBERON:0004720 | 97.29 | gold quality |
| inferior vagus X ganglion | UBERON:0005363 | 97.12 | gold quality |
| buccal mucosa cell | CL:0002336 | 96.91 | gold quality |
| lateral globus pallidus | UBERON:0002476 | 96.86 | gold quality |
| superior vestibular nucleus | UBERON:0007227 | 96.52 | gold quality |
| calcaneal tendon | UBERON:0003701 | 96.49 | gold quality |
| ventral tegmental area | UBERON:0002691 | 96.42 | gold quality |
| medulla oblongata | UBERON:0001896 | 96.10 | gold quality |
| substantia nigra pars reticulata | UBERON:0001966 | 96.03 | gold quality |
| colonic epithelium | UBERON:0000397 | 95.71 | gold quality |
| pigmented layer of retina | UBERON:0001782 | 95.68 | gold quality |
| substantia nigra pars compacta | UBERON:0001965 | 95.66 | gold quality |
| subthalamic nucleus | UBERON:0001906 | 95.58 | gold quality |
| nipple | UBERON:0002030 | 94.76 | gold quality |
| inferior olivary complex | UBERON:0002127 | 94.57 | gold quality |
| dorsal motor nucleus of vagus nerve | UBERON:0002870 | 94.54 | gold quality |
| saphenous vein | UBERON:0007318 | 94.54 | gold quality |
| tendon | UBERON:0000043 | 94.37 | gold quality |
| caput epididymis | UBERON:0004358 | 94.21 | gold quality |
| corpus epididymis | UBERON:0004359 | 94.19 | gold quality |
| mammary duct | UBERON:0001765 | 93.76 | gold quality |
| Brodmann (1909) area 46 | UBERON:0006483 | 93.76 | gold quality |
| parietal lobe | UBERON:0001872 | 93.67 | gold quality |
| sperm | CL:0000019 | 93.52 | gold quality |
| dorsal plus ventral thalamus | UBERON:0001897 | 93.44 | gold quality |
| postcentral gyrus | UBERON:0002581 | 93.21 | gold quality |
| superior surface of tongue | UBERON:0007371 | 92.96 | gold quality |
Single-cell (SCXA)
Detected in 2 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-GEOD-93593 | no | 10.55 |
| E-ANND-3 | no | 0.00 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
212 targeting TULP4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-5692A | 100.00 | 74.40 | 6850 |
| HSA-MIR-3613-3P | 100.00 | 76.36 | 7965 |
| HSA-MIR-30A-5P | 100.00 | 76.31 | 3233 |
| HSA-MIR-30B-5P | 100.00 | 76.29 | 3248 |
| HSA-MIR-30C-5P | 100.00 | 76.29 | 3248 |
| HSA-MIR-30D-5P | 100.00 | 76.32 | 3233 |
| HSA-MIR-30E-5P | 100.00 | 76.32 | 3242 |
| HSA-MIR-3646 | 100.00 | 73.56 | 5283 |
| HSA-MIR-4262 | 100.00 | 73.26 | 3931 |
| HSA-MIR-3163 | 100.00 | 77.23 | 8605 |
| HSA-MIR-340-5P | 100.00 | 72.50 | 4437 |
| HSA-MIR-3064-3P | 100.00 | 70.09 | 1254 |
| HSA-MIR-196A-1-3P | 99.99 | 72.15 | 2772 |
| HSA-MIR-371B-5P | 99.99 | 75.34 | 4759 |
| HSA-MIR-4282 | 99.99 | 75.36 | 6408 |
| HSA-MIR-181A-5P | 99.99 | 72.96 | 2995 |
| HSA-MIR-181B-5P | 99.99 | 72.97 | 2996 |
| HSA-MIR-181C-5P | 99.99 | 72.95 | 2996 |
| HSA-MIR-181D-5P | 99.99 | 73.04 | 2997 |
| HSA-MIR-3662 | 99.99 | 73.82 | 5684 |
| HSA-MIR-186-5P | 99.99 | 70.83 | 3707 |
| HSA-MIR-12121 | 99.99 | 66.64 | 255 |
| HSA-MIR-373-5P | 99.98 | 75.36 | 4753 |
| HSA-MIR-616-5P | 99.98 | 75.58 | 4775 |
| HSA-MIR-4803 | 99.98 | 71.99 | 3117 |
| HSA-MIR-12136 | 99.98 | 72.81 | 5713 |
| HSA-MIR-32-5P | 99.98 | 75.21 | 1964 |
| HSA-MIR-92A-3P | 99.98 | 75.21 | 1960 |
| HSA-MIR-92B-3P | 99.98 | 75.25 | 1955 |
| HSA-MIR-25-3P | 99.98 | 74.60 | 1817 |
Literature-anchored findings (GeneRIF, showing 2)
- In Philippines families, overtransmission of alleles to persons born with CL+/-P. Results : We found statistical evidence of association between a marker of TULP4 (rs651333) with CL+/-P (P = .00007). Conclusions : Our results further support the linkage results for the chromosome 6q region and reveal a novel candidate gene for CL+/-P. (PMID:24066709)
- Effects of Tulp4 deficiency on murine embryonic development and adult phenotype. (PMID:38115643)
Cross-species orthologs
6 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | tulp4a | ENSDARG00000045911 |
| danio_rerio | tulp4b | ENSDARG00000063056 |
| mus_musculus | Tulp4 | ENSMUSG00000034377 |
| rattus_norvegicus | Tulp4 | ENSRNOG00000018012 |
| drosophila_melanogaster | Tusp | FBGN0039530 |
| caenorhabditis_elegans | tub-2 | WBGENE00022139 |
Paralogs (5): TULP3 (ENSG00000078246), TULP2 (ENSG00000104804), TULP1 (ENSG00000112041), WDR35 (ENSG00000118965), TUB (ENSG00000166402)
Protein
Protein identifiers
Tubby-related protein 4 — Q9NRJ4 (reviewed: Q9NRJ4)
Alternative names: Tubby superfamily protein, Tubby-like protein 4
All UniProt accessions (2): Q9NRJ4, A0A087WYH3
UniProt curated annotations — full annotation on UniProt →
Function. May be a substrate-recognition component of a SCF-like ECS (Elongin-Cullin-SOCS-box protein) E3 ubiquitin ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins.
Subcellular location. Cytoplasm.
Tissue specificity. Expressed mainly in the brain, skeletal muscle, testis and kidney.
Domain organisation. The SOCS box domain mediates the interaction with the Elongin BC complex, an adapter module in different E3 ubiquitin ligase complexes.
Pathway. Protein modification; protein ubiquitination.
Similarity. Belongs to the TUB family.
Isoforms (2)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q9NRJ4-1 | 1 | yes |
| Q9NRJ4-2 | 2 |
RefSeq proteins (2): NP_001007467, NP_064630* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR000007 | Tubby_C | Domain |
| IPR001496 | SOCS_box | Domain |
| IPR001680 | WD40_rpt | Repeat |
| IPR008983 | Tumour_necrosis_fac-like_dom | Homologous_superfamily |
| IPR015943 | WD40/YVTN_repeat-like_dom_sf | Homologous_superfamily |
| IPR025659 | Tubby-like_C | Homologous_superfamily |
| IPR036322 | WD40_repeat_dom_sf | Homologous_superfamily |
| IPR056159 | Beta-prop_IFT121_TULP_N | Domain |
Pfam: PF01167, PF07525, PF24797
UniProt features (32 total): repeat 7, region of interest 6, sequence variant 6, modified residue 5, compositionally biased region 3, splice variant 2, chain 1, sequence conflict 1, domain 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q9NRJ4-F1 | 53.93 | 0.21 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (5): 577, 945, 950, 1343, 1374
Function
Pathways and Gene Ontology
Reactome pathways
1 pathways
| ID | Pathway |
|---|---|
| R-HSA-8951664 | Neddylation |
MSigDB gene sets: 202 (showing top):
RACCACAR_AML_Q6, HNF1_Q6, CACCAGC_MIR138, HEIDENBLAD_AMPLICON_8Q24_DN, YORDY_RECIPROCAL_REGULATION_BY_ETS1_AND_SP100_DN, chr6q25, AML_Q6, WTGAAAT_UNKNOWN, GOBP_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, BYSTRYKH_HEMATOPOIESIS_STEM_CELL_AND_BRAIN_QTL_TRANS, COATES_MACROPHAGE_M1_VS_M2_DN, CAIRO_HEPATOBLASTOMA_UP, TGTTTAC_MIR30A5P_MIR30C_MIR30D_MIR30B_MIR30E5P, MARKEY_RB1_ACUTE_LOF_UP, BURTON_ADIPOGENESIS_11
GO Biological Process (1): protein ubiquitination (GO:0016567)
GO Molecular Function (1): protein binding (GO:0005515)
GO Cellular Component (2): cytoplasm (GO:0005737), cytosol (GO:0005829)
Reactome top-level categories
Rollup of top-1 pathways:
| Category | Pathways |
|---|---|
| Post-translational protein modification | 1 |
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| cellular anatomical structure | 2 |
| protein modification by small protein conjugation | 1 |
| binding | 1 |
| intracellular anatomical structure | 1 |
| cytoplasm | 1 |
Protein interactions and networks
STRING
658 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| TULP4 | MISP | Q8IVT2 | 720 |
| TULP4 | SERAC1 | Q96JX3 | 593 |
| TULP4 | F8W876 | F8W876 | 578 |
| TULP4 | GTF2H5 | Q6ZYL4 | 534 |
| TULP4 | TMEM242 | Q9NWH2 | 526 |
| TULP4 | TMEM181 | Q9P2C4 | 481 |
| TULP4 | RIMS2 | Q9UQ26 | 470 |
| TULP4 | ATPSCKMT | Q6P4H8 | 468 |
| TULP4 | GREB1L | Q9C091 | 464 |
| TULP4 | PCNP | Q8WW12 | 461 |
| TULP4 | IGDCC4 | Q8TDY8 | 456 |
| TULP4 | SCAF8 | Q9UPN6 | 450 |
| TULP4 | CUL5 | Q93034 | 445 |
| TULP4 | KLHL2 | O95198 | 440 |
| TULP4 | KCNE4 | Q8WWG9 | 425 |
IntAct
20 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| CUL5 | SOCS2 | psi-mi:“MI:0914”(association) | 0.880 |
| CUL5 | SOCS7 | psi-mi:“MI:0914”(association) | 0.640 |
| RNF7 | SOCS7 | psi-mi:“MI:0914”(association) | 0.530 |
| NEDD4 | TULP4 | psi-mi:“MI:0407”(direct interaction) | 0.440 |
| ABL1 | TULP4 | psi-mi:“MI:0915”(physical association) | 0.400 |
| SRC | TULP4 | psi-mi:“MI:0915”(physical association) | 0.400 |
| TULP4 | FYN | psi-mi:“MI:0915”(physical association) | 0.400 |
| TULP4 | PIK3R1 | psi-mi:“MI:0915”(physical association) | 0.400 |
| CUL5 | DDX3X | psi-mi:“MI:0914”(association) | 0.350 |
| MAGI1 | CIT | psi-mi:“MI:0914”(association) | 0.350 |
| ATG16L1 | ESYT2 | psi-mi:“MI:0914”(association) | 0.350 |
| WWP2 | CCDC85C | psi-mi:“MI:0914”(association) | 0.350 |
| FAM168A | CCDC85C | psi-mi:“MI:0914”(association) | 0.350 |
| RNF7 | SOCS2 | psi-mi:“MI:0914”(association) | 0.350 |
| TULP4 | CASK | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (40): TULP4 (Affinity Capture-MS), TULP4 (Affinity Capture-RNA), TULP4 (Affinity Capture-RNA), TULP4 (Affinity Capture-MS), TULP4 (Affinity Capture-RNA), TULP4 (Affinity Capture-MS), TULP4 (Affinity Capture-MS), TULP4 (Affinity Capture-MS), TULP4 (Affinity Capture-MS), TULP4 (Affinity Capture-MS), TULP4 (Affinity Capture-MS), TSEN15 (Affinity Capture-MS), BAG3 (Affinity Capture-MS), STXBP4 (Affinity Capture-MS), CASK (Affinity Capture-MS)
ESM2 similar proteins: A1ZA47, B6RSP1, O14964, O17583, O35625, O42400, O54916, O60885, O74252, O75553, P0C090, P15330, P16554, P49757, P57094, P97318, P98078, Q0V8S0, Q21502, Q24212, Q24478, Q2LC84, Q5F464, Q5TYQ8, Q5XI07, Q62415, Q641G3, Q69ZW3, Q6DFF2, Q6NUC6, Q75BK1, Q8BG30, Q8CJH2, Q8IPJ3, Q8NDI1, Q96D71, Q96KQ4, Q9BGX5, Q9H3P2, Q9HBD1
Diamond homologs: A0A644F0T7, Q9JIL5, Q9NRJ4, A8WN62, B0WI30, B0XFQ9, B3MDU3, B3NJY0, B4H4X0, B4I7J9, B4J6R7, B4KNA9, B4LMR9, B4MKC7, B4P9H8, B4QFM2, O00294, O00295, O75386, O88413, O88808, P46686, P50586, P50607, Q09306, Q0WPY0, Q10LG8, Q16IR1, Q16KI5, Q28X18, Q2QXB2, Q53PP5, Q5QM27, Q688Y7, Q68Y48, Q69U54, Q6NPQ1, Q6Z2G9, Q75HX5, Q7PZK5
SIGNOR signaling
0 interactions.
Enriched among interaction partners
Reactome pathways and GO biological processes over-represented among this gene’s 18 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.
GO biological processes:
| GO term | Partners | Fold | FDR |
|---|---|---|---|
| protein ubiquitination | 7 | 16.1× | 5e-05 |
| proteasome-mediated ubiquitin-dependent protein catabolic process | 5 | 14.5× | 7e-04 |
| intracellular signal transduction | 6 | 12.7× | 3e-04 |
Disease & clinical
Clinical variants and AI predictions
ClinVar
330 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 281 |
| Likely benign | 20 |
| Benign | 3 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
3600 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 6:158429733:AAGGT:A | acceptor_gain | 1.0000 |
| 6:158429735:GG:G | acceptor_loss | 1.0000 |
| 6:158429735:GGTGA:G | acceptor_gain | 1.0000 |
| 6:158429895:CAGG:C | donor_loss | 1.0000 |
| 6:158429896:AG:A | donor_loss | 1.0000 |
| 6:158452132:A:AG | acceptor_gain | 1.0000 |
| 6:158452132:AGAT:A | acceptor_gain | 1.0000 |
| 6:158452133:G:GT | acceptor_gain | 1.0000 |
| 6:158452133:GAT:G | acceptor_gain | 1.0000 |
| 6:158452133:GATG:G | acceptor_gain | 1.0000 |
| 6:158452265:AAAG:A | donor_loss | 1.0000 |
| 6:158452267:AGG:A | donor_loss | 1.0000 |
| 6:158452268:GGTAC:G | donor_loss | 1.0000 |
| 6:158452269:GTAC:G | donor_loss | 1.0000 |
| 6:158452270:T:G | donor_loss | 1.0000 |
| 6:158461558:TTCA:T | acceptor_loss | 1.0000 |
| 6:158461559:TCA:T | acceptor_loss | 1.0000 |
| 6:158461560:CA:C | acceptor_loss | 1.0000 |
| 6:158461561:A:AG | acceptor_gain | 1.0000 |
| 6:158461561:AGAG:A | acceptor_gain | 1.0000 |
| 6:158461562:G:GA | acceptor_gain | 1.0000 |
| 6:158461562:GA:G | acceptor_gain | 1.0000 |
| 6:158461562:GAGG:G | acceptor_gain | 1.0000 |
| 6:158461562:GAGGT:G | acceptor_gain | 1.0000 |
| 6:158461728:AGG:A | donor_loss | 1.0000 |
| 6:158461729:GGTA:G | donor_loss | 1.0000 |
| 6:158461730:G:C | donor_loss | 1.0000 |
| 6:158479750:GC:G | acceptor_gain | 1.0000 |
| 6:158479904:G:GT | donor_gain | 1.0000 |
| 6:158479972:CAAG:C | donor_loss | 1.0000 |
AlphaMissense
10049 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 6:158314080:T:A | W22R | 1.000 |
| 6:158314080:T:C | W22R | 1.000 |
| 6:158314153:T:C | L46P | 1.000 |
| 6:158314249:T:C | L78P | 1.000 |
| 6:158413080:T:A | W90R | 1.000 |
| 6:158413080:T:C | W90R | 1.000 |
| 6:158413082:G:C | W90C | 1.000 |
| 6:158413082:G:T | W90C | 1.000 |
| 6:158413102:T:C | L97P | 1.000 |
| 6:158413105:C:A | A98D | 1.000 |
| 6:158413129:T:A | I106K | 1.000 |
| 6:158413137:T:A | W109R | 1.000 |
| 6:158413137:T:C | W109R | 1.000 |
| 6:158413158:T:A | W116R | 1.000 |
| 6:158413158:T:C | W116R | 1.000 |
| 6:158413160:G:C | W116C | 1.000 |
| 6:158413160:G:T | W116C | 1.000 |
| 6:158413171:T:A | L120Q | 1.000 |
| 6:158413171:T:C | L120P | 1.000 |
| 6:158429746:T:C | F131S | 1.000 |
| 6:158429751:T:A | W133R | 1.000 |
| 6:158429751:T:C | W133R | 1.000 |
| 6:158429752:G:C | W133S | 1.000 |
| 6:158429753:G:C | W133C | 1.000 |
| 6:158429753:G:T | W133C | 1.000 |
| 6:158429763:G:A | G137R | 1.000 |
| 6:158429763:G:C | G137R | 1.000 |
| 6:158429764:G:A | G137E | 1.000 |
| 6:158429764:G:T | G137V | 1.000 |
| 6:158429776:T:C | L141P | 1.000 |
dbSNP variants (sampled 300 via entrez): RS1000001719 (6:158292667 C>T), RS1000002267 (6:158230668 T>C), RS1000004803 (6:158461424 A>G), RS1000040495 (6:158329922 A>G), RS1000041505 (6:158396225 C>T), RS1000047133 (6:158319152 C>T), RS1000052794 (6:158464721 GA>G,GAA), RS1000053269 (6:158381949 T>C), RS1000069453 (6:158253072 A>G), RS1000085534 (6:158333859 C>A), RS1000087026 (6:158437003 A>G), RS1000096463 (6:158230808 T>C), RS1000100374 (6:158475263 C>T), RS1000106776 (6:158415349 C>T), RS1000107623 (6:158332452 G>C)
Disease associations
OMIM: gene MIM:619442 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
10 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST000817_105 | Height | 2.000000e-09 |
| GCST002647_63 | Height | 2.000000e-15 |
| GCST003127_10 | Lipoprotein (a) levels | 4.000000e-10 |
| GCST006979_717 | Heel bone mineral density | 1.000000e-13 |
| GCST008163_104 | Height | 7.000000e-06 |
| GCST008163_248 | Height | 8.000000e-07 |
| GCST012232_12 | Lipoprotein (a) levels | 5.000000e-12 |
| GCST90000025_138 | Appendicular lean mass | 6.000000e-23 |
| GCST90002400_597 | Plateletcrit | 5.000000e-11 |
| GCST90002407_533 | White blood cell count | 1.000000e-10 |
EFO canonical traits (4, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0006925 | lipoprotein A measurement |
| EFO:0009270 | heel bone mineral density |
| EFO:0004980 | appendicular lean mass |
| EFO:0007985 | platelet crit |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
36 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Benzo(a)pyrene | affects methylation, decreases expression | 5 |
| bisphenol A | decreases methylation, affects cotreatment, decreases expression | 2 |
| Tretinoin | decreases expression, increases expression | 2 |
| Cadmium Chloride | increases expression | 2 |
| aristolochic acid I | decreases expression | 1 |
| GSK-J4 | increases expression | 1 |
| FR900359 | affects phosphorylation | 1 |
| dicrotophos | increases expression | 1 |
| triphenyl phosphate | affects expression | 1 |
| geraniol | increases expression | 1 |
| sodium arsenite | increases expression | 1 |
| butyraldehyde | decreases expression | 1 |
| potassium chromate(VI) | affects cotreatment, decreases expression | 1 |
| 2,3-bis(3’-hydroxybenzyl)butyrolactone | affects cotreatment, decreases expression | 1 |
| aflatoxin B2 | increases methylation | 1 |
| epigallocatechin gallate | decreases expression, increases expression, affects cotreatment | 1 |
| CGP 52608 | affects binding, increases reaction | 1 |
| Vorinostat | decreases expression | 1 |
| Leflunomide | increases expression | 1 |
| Panobinostat | increases expression | 1 |
| Acetaminophen | increases expression | 1 |
| Camptothecin | decreases expression | 1 |
| Cisplatin | decreases expression | 1 |
| Coumestrol | affects cotreatment, decreases expression | 1 |
| Dexamethasone | affects cotreatment, decreases expression | 1 |
| Indomethacin | affects cotreatment, decreases expression | 1 |
| Mercuric Chloride | decreases expression | 1 |
| Urethane | increases expression | 1 |
| Valproic Acid | increases methylation | 1 |
| Vincristine | increases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.